Nadolol
- Generic Name
- Nadolol
- Brand Names
- Corgard
- Drug Type
- Small Molecule
- Chemical Formula
- C17H27NO4
- CAS Number
- 42200-33-9
- Unique Ingredient Identifier
- FEN504330V
- Background
Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure. Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects.
Nadolol was granted FDA approval on 10 December 1979.
- Indication
Nadolol is indicated to treat angina pectoris and hypertension. Another product formulated with bendroflumethiazide is indicated to treat hypertension.
- Associated Conditions
- Angina Pectoris, Atrial Fibrillation, Gastroesophageal variceal hemorrhage prophylaxis, Hypertension, Migraine, Thyrotoxicosis
- Associated Therapies
- -
Nadolol Versus Propranolol in Children With Infantile Hemangiomas
- First Posted Date
- 2015-07-22
- Last Posted Date
- 2020-10-28
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 74
- Registration Number
- NCT02505971
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
Efficacy and Safety of Î’eta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction
- First Posted Date
- 2013-04-05
- Last Posted Date
- 2017-02-01
- Lead Sponsor
- Invion, Inc.
- Target Recruit Count
- 155
- Registration Number
- NCT01825122
- Locations
- 🇺🇸
Nuren Medical, Miami, Florida, United States
🇺🇸Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸Abel Buchheim Pharmaceutical Research, Miami, Florida, United States
Efficacy and Safety of Beta-adrenoceptor Inverse Agonist, Nadolol, in Mild Asthma
- First Posted Date
- 2013-03-05
- Last Posted Date
- 2016-08-09
- Lead Sponsor
- Invion, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT01804218
- Locations
- 🇺🇸
Washington University School of Medicine, St. Louis, Missouri, United States
🇺🇸Baylor College of Medicine, Houston, Texas, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Nadolol for Proliferating Infantile Hemangiomas
- First Posted Date
- 2009-11-10
- Last Posted Date
- 2021-08-19
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 20
- Registration Number
- NCT01010308
- Locations
- 🇨🇦
The Hospital for Sick Children, Toronto, Ontario, Canada
A Trial of Ligation Plus Nadolol Versus Nadolol Alone in the Prophylaxis of First Variceal Bleeding in Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2009-06-16
- Last Posted Date
- 2009-06-16
- Lead Sponsor
- National Science Council, Taiwan
- Target Recruit Count
- 140
- Registration Number
- NCT00921349
Oral Nadolol for the Treatment of Adults With Mild Asthma
- First Posted Date
- 2008-05-01
- Last Posted Date
- 2016-05-11
- Lead Sponsor
- Invion, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00670267
- Locations
- 🇺🇸
Baylor College of Medicine, Houston, Texas, United States
Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding
- First Posted Date
- 2007-12-04
- Last Posted Date
- 2010-06-08
- Lead Sponsor
- Taipei Veterans General Hospital, Taiwan
- Target Recruit Count
- 120
- Registration Number
- NCT00567216
- Locations
- 🇨🇳
Veteran General Hospital-Taipei, Taipei city, Taiwan, China
Secondary Prophylaxis After Variceal Bleeding in Non-Responders
- Conditions
- First Posted Date
- 2007-03-21
- Last Posted Date
- 2007-03-21
- Target Recruit Count
- 50
- Registration Number
- NCT00450164
- Locations
- 🇪🇸
Unidad de Sangrantes, HSCSP, Barcelona, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.